| Zach Robert Boal, MD | |
|
5325 Faraon St, Saint Joseph, MO 64506-3488 | |
| (816) 271-6000 | |
| Not Available |
| Full Name | Zach Robert Boal |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 6 Years |
| Location | 5325 Faraon St, Saint Joseph, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053805531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | LL52792 (South Carolina) | Secondary |
| 207P00000X | Emergency Medicine | 2021016111 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mosaic Medical Center Albany | Albany, MO | Hospital |
| Ssm Health St. Francis Hospital- Maryville | Maryville, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mosaic Medical Center - Maryville | 3678813896 | 89 |
| Northwest Medical Center Association Inc | 5496641896 | 19 |
News Archive
Two Minnesota lawmakers are pushing a bill to help veterans with post-traumatic stress disorder who may have been discharged from the military after being diagnosed inaccurately.
The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.
Australian researchers have developed the country's first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
| Entity Name | Northwest Medical Center Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124164322 PECOS PAC ID: 5496641896 Enrollment ID: O20040224000204 |
News Archive
Two Minnesota lawmakers are pushing a bill to help veterans with post-traumatic stress disorder who may have been discharged from the military after being diagnosed inaccurately.
The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.
Australian researchers have developed the country's first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
| Entity Name | Heartland Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477575405 PECOS PAC ID: 6709772767 Enrollment ID: O20040225001201 |
News Archive
Two Minnesota lawmakers are pushing a bill to help veterans with post-traumatic stress disorder who may have been discharged from the military after being diagnosed inaccurately.
The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.
Australian researchers have developed the country's first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
| Entity Name | Mosaic Medical Center - Maryville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184189797 PECOS PAC ID: 3678813896 Enrollment ID: O20190405001537 |
News Archive
Two Minnesota lawmakers are pushing a bill to help veterans with post-traumatic stress disorder who may have been discharged from the military after being diagnosed inaccurately.
The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.
Australian researchers have developed the country's first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zach Robert Boal, MD Emergency Medicine Department, 14 Medical Park, Ste 350, Columbia, SC 29203 Ph: (803) 434-7088 | Zach Robert Boal, MD 5325 Faraon St, Saint Joseph, MO 64506-3488 Ph: (816) 271-6000 |
News Archive
Two Minnesota lawmakers are pushing a bill to help veterans with post-traumatic stress disorder who may have been discharged from the military after being diagnosed inaccurately.
The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.
Australian researchers have developed the country's first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
› Verified 7 days ago
Dr. Crystal Renae Macaluso, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6445 | |
Dr. Lilane J Reifenberg, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-561-1025 | |
Jean Laubinger, MD Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6122 Fax: 816-271-6019 | |
Mr. Scott Alan Franksen, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2303 Village Dr, Saint Joseph, MO 64506 Phone: 816-232-6818 Fax: 816-232-6823 | |
Michelle Ann Spieker, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6122 Fax: 816-271-6019 | |
Dr. Evan Richard Slanczka, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5325 Faraon St, Saint Joseph, MO 64506 Phone: 816-271-6122 Fax: 816-271-6019 |